Ceribell

Biophysicist-turned-medtech executive with a B.S. in chemistry from Peking University and a Ph.D. in biophysics from Cornell. She worked at McKinsey & Company, Novartis, and Genentech before co-founding Ceribell in 2015 with two Stanford professors. She has served as CEO and board member since the company's inception and led it from concept through its $200 million IPO — a rare founder-CEO arc in medtech. Ceribell's FDA-cleared EEG system enables rapid seizure detection in ICUs, addressing about three million patients in the US annually.

Professor of Neurology and Neurological Sciences at Stanford University Medical Center, specialising in brain mapping and epilepsy. He holds an M.D. and Ph.D. in Neuroscience from the University of Oslo. In 2014 he co-invented the Ceribell prototype — a disposable, flexible headband with a pocket-sized wireless EEG recorder that non-specialist providers can apply within minutes, replacing cumbersome conventional EEG setups. His clinical and scientific authority in epilepsy monitoring is the primary medical foundation for Ceribell's FDA-cleared Rapid Response EEG system.

Composer, cellist, and Director of the Center for Computer Research in Music and Acoustics (CCRMA) at Stanford University. He holds a Ph.D. in composition from Stanford (1983) and has pioneered digital synthesis and real-time internet music performance at IRCAM (Paris) and The Banff Centre. His unique contribution to Ceribell is the auditory sonification layer — he is named on a US patent for "systems and methods for processing sonified brain signals" — which converts EEG patterns into sound signatures that clinicians can quickly learn to interpret as normal or seizure activity.